dr-01
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 13, 2022 (NCT05475925)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Alopecia Areata · Phase 1
- Enteropathy-Associated T-Cell Lymphoma · Phase 1/Phase 2
- Healthy Volunteers · Phase 1
- Intestinal Neoplasms · Phase 1/Phase 2
- Leukemia, Large Granular Lymphocytic · Phase 1/Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Lymphoma · Phase 1/Phase 2
- Lymphoma, Extranodal NK-T-Cell · Phase 1/Phase 2
- Lymphoma, T-Cell · Phase 1/Phase 2
- Lymphoma, T-Cell, Cutaneous · Phase 1/Phase 2
- Lymphoma, T-Cell, Peripheral · Phase 1/Phase 2
- Lymphoproliferative Disorders · Phase 1/Phase 2
- Vitiligo · Phase 1
Mechanism of action
- Natural killer cells antigen CD94INHIBITOR
inhibitor - CD94
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06766864 | Phase 1 | Mar 3, 2025 | Dren Bio |
| NCT06602232 | Phase 1 | Oct 30, 2024 | Dren Bio |
| NCT05475925 | Phase 1/Phase 2 (Phase 2) | Jul 13, 2022 | Dren Bio, Novotech |
Showing 3 of 3 trials
Page 1 / 1